IOL Chemicals and Pharmaceuticals Research Report

Summary

Core view: IOLCP has moved from an earnings trough into a broad operating recovery. Q1 FY27 growth was led mainly by volume, utilisation, exports and internal efficiency—not an inventory or other-income windfall. However, at roughly 32 times trailing earnings, the market already prices in a meaningful portion of the FY27 recovery.

The investment case has three layers: near-term earnings recovery from fuller utilisation; medium-term diversification through non-ibuprofen APIs, formulations CDMO and specialty-chemical tolling; and a longer-dated ₹350 crore expansion that lifts ibuprofen capacity by 50%. The first is visible, the second needs commercial proof, and the third increases both scale and concentration.

Bottom line: operational momentum is positive, the balance sheet is comfortable, and Q3 FY27 can introduce two new contracted businesses. Yet the current valuation leaves limited protection if margins fall back toward 12%, raw-material pass-through lags, or the new projects ramp slowly. This is best viewed as a growth-execution story at a full valuation, not a deep-value chemical cycle trade.

Q1 FY27 Snapshot

Revenue₹756.3 Cr+37.1% YoY; +22.1% QoQ

EBITDA₹111.7 Cr+60.7% YoY

EBITDA Margin14.6%Vs 12.4% in Q1 FY26

PAT₹64.5 Cr+89.9% YoY

Metric	Q1 FY27	Q1 FY26	Q4 FY26	Read-through
Revenue from operations	₹756.3 Cr	₹551.7 Cr	₹619.5 Cr	Strong volume-led acceleration
EBITDA	₹111.7 Cr	₹69.5 Cr	₹94.3 Cr	Profit grew faster than revenue
EBITDA margin	14.6%	12.4%	15.2%	YoY expansion, modest QoQ normalisation
PAT	₹64.5 Cr	₹34.0 Cr	₹53.2 Cr	No exceptional item identified
Exports	28.5% of revenue	24.4%	Not disclosed here	Better international and regulated-market mix
Non-ibuprofen share	43% of pharma revenue	36%	38%	Diversification is accelerating

Management explicitly denied any meaningful Q1 inventory gain. It attributed the result to higher capacity utilisation, better operating efficiency, stronger non-ibuprofen demand, higher exports and some finished-product price improvement.

Business Quality And Mix

IOLCP is an integrated API and chemicals manufacturer. Its competitive advantage is process efficiency and backward integration rather than patented products. It manufactures key ibuprofen inputs such as Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride in-house.

Business	Q1 FY27 Revenue	Q1 FY27 EBIT	Position And Direction
Pharmaceuticals	₹469.5 Cr	₹68.8 Cr	+42.6% revenue YoY; non-ibuprofen APIs reached 43% of pharma revenue
Chemicals, net of intersegment	₹286.8 Cr	₹17.3 Cr	+29.0% revenue YoY; benefited from utilisation, realisations and exports

What Is Improving

API diversification: non-ibuprofen revenue grew 67% YoY, led by paracetamol, clopidogrel, pantoprazole, metformin, fenofibrate and other APIs.
Regulated-market access: the company reports 21 CEPs and 14 US DMFs. Clopidogrel received NMPA approval in China; management said most exported non-ibuprofen volumes go to regulated markets.
Capacity absorption: most established API plants operated at approximately 80-95%; paracetamol utilisation was about 55% on its enlarged 10,800 MTPA base.
Customer diversification: CARE reported that the top 10 customers represented only about 19% of FY26 sales.

Diversification is incomplete. CARE reported that ibuprofen and ethyl acetate together still generated approximately 68% of FY26 sales. These are scale products with meaningful commodity and spread sensitivity.

Why Earnings Improved

Structural Drivers

Higher utilisation across established API assets.
Paracetamol ramp on an automated, backward-integrated plant.
Rising regulated-market and export contribution.
Broader non-ibuprofen API portfolio.
Operating leverage on prior capex.

Cyclical Drivers

Improved ethyl acetate realisations and spreads.
Recovered ibuprofen demand after customer destocking.
Product-price increases following raw-material inflation.
Favourable demand across domestic and export markets.

The distinction matters. Utilisation, product mix and export penetration can support a higher earnings base. Chemical spreads and ibuprofen pricing can reverse. Q1 EBITDA margin of 14.6% is credible as an FY27 target, but it should not automatically be treated as a permanent floor.

Catalysts And ₹495 Crore Expansion

Project	Investment / Capacity	Timeline	Investment Read-through
Ibuprofen expansion	₹350 Cr; +6,000 MTPA, taking capacity from 12,000 to 18,000 MTPA	Commercialisation expected by December 2027	Large growth option backed by 95% existing utilisation, but increases exposure to one cyclical API
Formulations CDMO	₹110 Cr already invested; 1,500 million tablets annually or equivalent direct-compressible-grade volume	Expected Q3 FY27	Customer-led extension for European anchor customers; can move IOL higher in the value chain
Specialty-chemical tolling	₹35 Cr dedicated facility	Expected Q3 FY27	Long-term international customer and exclusive supply can improve revenue visibility; economics remain undisclosed
Triacetin	6,000 MTPA; estimated ₹120 Cr annual revenue potential at steady state	Production started after May 2026	New chemical product and import-substitution opportunity; early ramp stage
Paracetamol ramp	10,800 MTPA installed capacity	70-75% utilisation targeted in FY27; full utilisation targeted in FY28	Near-term volume and operating-leverage driver

The September announcement came after management's earlier FY27 capex guidance of ₹200-250 crore. The ₹350 crore ibuprofen project runs through December 2027, while the CDMO plant is already installed. Investors should reconcile annual cash outflow, project phasing and free-cash-flow impact in subsequent disclosures.

All three September projects are to be funded through internal accruals. That protects leverage, but creates a capital-allocation test: trailing free cash flow was modest relative to the announced project pipeline, so execution may absorb cash that would otherwise support dividends or buybacks.

Management Guidance And Credibility Check

Management Statement	Assessment
FY27 revenue growth of 15-20%	Implies approximately ₹2,667-2,783 Cr. Q1 already delivered ₹756 Cr, so the target is achievable if demand normalises rather than reverses.
FY27 EBITDA margin of 14-15%	Q1 was 14.6%. This appears reasonable, but raw-material pass-through timing and chemical spreads remain variables.
Exports at 25-30% of revenue	Q1 reached 28.5%. Contract dispatch timing can make this lumpy by quarter.
FY28 revenue growth around 15-20% and EBITDA margin around 15-17%	Management immediately qualified this as scenario-dependent. Treat it as an aspiration, not formal guidance.
Non-ibuprofen share of API revenue at 50-55% by FY29	Plausible from 43% in Q1 FY27, but the new ibuprofen capacity may slow the percentage shift after commissioning.

Management's FY26 guidance was followed by improving revenue and margin, and it did not claim a Q1 inventory windfall. Positively, it generally avoids disclosing product-level margins it cannot support. Negatively, project economics for formulations CDMO and tolling—revenue potential, margins, minimum offtake and contract duration—remain absent.

Financial Quality And Balance Sheet

FY26 Equity₹1,798 CrStrong accumulated net worth

FY26 Borrowings₹132 CrNo term debt; mainly working capital

Cash + Bank₹198 CrBefore liquid investments

CARE RatingA+ / A1+Stable; reaffirmed July 2026

Metric	FY26	Interpretation
Operating cash flow	₹214.4 Cr	Good conversion against ₹137.7 Cr PAT
Investing cash flow	₹(198.1) Cr	Business remains capex-intensive
Approximate free cash flow	₹16 Cr	Positive but thin before the new expansion cycle
Trade receivables	₹603.1 Cr	High at about 26% of annual revenue; monitor collection
Operating cycle	73 days	Improved from 78 days, according to CARE
ROCE / ROE	About 11.3% / 8.4%	Still modest; rerating needs sustained improvement

The balance sheet can support the announced capex, but the key quality issue is return on incremental capital. IOL has added substantial fixed assets over recent years while returns remain low-double-digit. The CDMO and tolling projects need to lift asset turns and margins—not merely revenue—to justify a premium multiple.

Valuation: Recovery Is No Longer Cheap

At the 11 September 2026 close of ₹194.31, market capitalisation was approximately ₹5,704 crore. Screener reported trailing EPS of ₹5.72 and a P/E of about 32.3 times. On FY26 book value, the stock traded near 3.2 times book despite single-digit ROE.

Measure	Approximate Value	Interpretation
Trailing P/E	32.3x	Full for a business with commodity exposure and 8-9% trailing ROE
Trailing EV / EBITDA	~18x	Assumes ₹5,704 Cr market cap and modest net cash; not a trough multiple
Illustrative FY27 EPS	₹7.5-8.8	Based on ₹220-260 Cr PAT and approximately 29.35 Cr shares
FY27 forward P/E	~22-26x	More reasonable, but requires guidance delivery

Scenario Valuation

Case	FY27 PAT	Assigned P/E	Indicative Value / Share	What Must Happen
Bear	₹185 Cr	18x	~₹113	Margins return near 12-13%; projects ramp slowly
Base	₹230 Cr	24x	~₹188	FY27 guidance met; Q3 projects start without a major surprise
Bull	₹265 Cr	28x	~₹253	15%+ margin, regulated exports and CDMO/tolling scale cleanly

Valuation conclusion: ₹194 is close to the base-case value under these assumptions. Upside requires IOL to evolve from an efficient commodity/API producer into a higher-return, contracted manufacturing platform. Q1 recovery alone is largely reflected in the price.

Scenario values are analytical illustrations, not price targets. Different multiples, tax rates, share counts or cycle assumptions can materially change the outcome.

Key Risks

Business Risks

Ibuprofen and ethyl acetate concentration remains high.
Commodity prices and raw-material spreads can compress quickly.
Imported DCDA creates China dependence for metformin.
Regulatory observations can disrupt regulated-market sales.
New CDMO and tolling economics are not yet transparent.

Financial And Execution Risks

₹495 Cr project pipeline can suppress free cash flow.
Receivables remain elevated.
New ibuprofen supply may pressure industry pricing.
December 2027 commissioning can slip or overrun.
Current valuation magnifies disappointment risk.

The central contradiction is strategic: IOL says it wants to reduce ibuprofen dependence, yet its largest announced project adds 50% to ibuprofen capacity. This can create value if global demand and customer commitments absorb the output; otherwise it can dilute returns and intensify price competition.

Projection: Next 2-4 Quarters

Assumptions: established assets sustain high utilisation; paracetamol ramps; export mix remains near guidance; Q3 includes initial formulations CDMO and tolling revenue; EBITDA margin stays within management's 14-15% range; no major inventory gain or regulatory disruption.

Period	Revenue Estimate	Expected OPM	Expected EBITDA Margin	EBITDA Estimate	PAT Estimate	Expected EPS	Key Variable
Q2 FY27	₹675-725 Cr	13.5-14.5%	14.0-15.0%	₹95-108 Cr	₹54-64 Cr	₹1.84-2.18	Normalisation after a very strong Q1
Q3 FY27	₹690-750 Cr	13.5-14.5%	14.0-15.0%	₹98-113 Cr	₹56-67 Cr	₹1.91-2.28	Initial CDMO and tolling commercialisation
Q4 FY27	₹660-720 Cr	13.5-14.5%	14.0-15.0%	₹94-108 Cr	₹53-63 Cr	₹1.81-2.15	Contract ramp and chemical spreads
Q1 FY28	₹775-835 Cr	14.0-15.0%	14.5-15.5%	₹112-128 Cr	₹65-76 Cr	₹2.21-2.59	Higher paracetamol and contracted-business scale

FY27 Scenario	Revenue	Expected OPM	Expected EBITDA Margin	PAT	Expected EPS
Conservative	₹2,550-2,650 Cr	12.0-13.0%	12.5-13.5%	₹180-205 Cr	₹6.13-6.98
Base	₹2,680-2,780 Cr	13.5-14.2%	14.0-14.7%	₹220-245 Cr	₹7.50-8.35
Optimistic	₹2,800-2,900 Cr	14.5-15.0%	15.0-15.5%	₹250-270 Cr	₹8.52-9.20

Expected EPS uses approximately 29.35 crore shares outstanding and assumes no material dilution.

The base case is broadly aligned with management guidance. The quarter-by-quarter pattern may be uneven because export contracts, price pass-through and new-project dispatches can be lumpy.

Investor Watchlist

Does EBITDA margin remain at or above 14% without inventory benefits?
Does non-ibuprofen reach 50% of pharma revenue before new ibuprofen capacity starts?
Does paracetamol utilisation reach the 70-75% FY27 target?
Do formulations CDMO and specialty tolling commercialise in Q3 FY27 as guided?
What revenue, EBITDA margin, contract duration and minimum offtake do the new projects carry?
How is the ₹350 crore ibuprofen capex phased, and what return on capital is expected?
Do receivable days and working-capital borrowings remain controlled?
Does operating cash flow fund capex without eroding liquidity or increasing debt materially?
Are USFDA, EU-GMP, ANVISA, NMPA and customer audits completed without adverse observations?
Does ROCE move sustainably above 15%, the level needed to support a premium valuation?

Sources Used

Prepared on 12 September 2026 using public information available up to that date. Estimates and scenario values are the author's analytical assumptions and are not company guidance. This report is not a recommendation to buy, sell, or hold securities. Verify all figures against original exchange filings before making an investment decision.